A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Range Finding Study To Determine The Efficacy And Safety Of Fedovapagon In Men With Nocturia
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2013
At a glance
- Drugs Fedovapagon (Primary)
- Indications Nocturia
- Focus Therapeutic Use
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jun 2013 Planned end date changed from 1 May 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 11 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.